<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4721">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01708902</url>
  </required_header>
  <id_info>
    <org_study_id>1288.18</org_study_id>
    <nct_id>NCT01708902</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients</brief_title>
  <official_title>A Phase III Randomised, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Fix Dose Combination of Linagliptin 2.5 mg + Metformin 500 mg, or of Linagliptin 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg, Twice Daily), and Linagliptin (5.0 mg, Once Daily) Over 24 Weeks in Treatment naïve Type 2 Diabetic Patients With Insufficient Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <authority>Malaysia: Ministry of Health</authority>
    <authority>Philippines: Bureau of Food and Drugs</authority>
    <authority>Vietnam: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduced factorial design study with 24 week randomized treatment of initial combination
      therapy with linagliptin and metformin in T2DM patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The change from baseline in HbA1c after 24 weeks of treatment (for both in main group and additional parallel group).</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of treat to target efficacy response in terms of HbA1c &lt; 7.0 % and &lt; 6.5% after 24 weeks of treatment</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of relative efficacy response (HbA1c lowering by at least 0.5% after 24 weeks of treatment)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in fasting plasma glucose (FPG) from baseline after 24 weeks of treatment</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of patients with use of rescue therapy during 24 week treatment period.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">876</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>linagliptin2.5mg / metformin500mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>linagliptin2.5mg / metformin1000mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin 500mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive a tablet containing metformin 500mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin 1000mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive a tablet containing metformin 1000mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>linagliptin 5 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive a tablet containing linagliptin 5mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin2.5mg/metformin1000mg</intervention_name>
    <description>linagliptin2.5mg/metformin1000mg BID</description>
    <arm_group_label>metformin 1000mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin2.5mg/metformin1000mg</intervention_name>
    <description>linagliptin2.5mg/metformin1000mg BID</description>
    <arm_group_label>linagliptin 5 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin 5mg</intervention_name>
    <description>linagliptin 5mg  once daily</description>
    <arm_group_label>linagliptin2.5mg / metformin500mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 500mg</intervention_name>
    <description>Metformin 500mg BID</description>
    <arm_group_label>linagliptin2.5mg / metformin500mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin2.5mg/metformin500mg</intervention_name>
    <description>linagliptin2.5mg/metformin500mg BID</description>
    <arm_group_label>metformin 500mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin2.5mg/metformin500mg</intervention_name>
    <description>linagliptin2.5mg/metformin500mg BID</description>
    <arm_group_label>linagliptin 5 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin 5mg</intervention_name>
    <description>linagliptin 5mg  once daily</description>
    <arm_group_label>linagliptin2.5mg / metformin1000mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1000mg</intervention_name>
    <description>Metformin 1000mg BID</description>
    <arm_group_label>linagliptin2.5mg / metformin1000mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of Type 2 diabetes mellitus(T2DM) prior to informed consent

          2. Male and female patients on diet and exercise regimen who are drug-naïve

          3. Glycosylated haemoglobin A1c (HbA1c) at V1a &gt;/=7.5 %&lt;11% for main group and HbA1c &gt;/=
             11.0 % for the additional parallel group

          4. Age &gt;/= 18 and &lt;/= 80 years at Visit 1a (Screening)

          5. Body Mass Index(BMI)&lt;/ = 40 kg/m2 at Visit 1a (Screening)

          6. Signed and dated written informed consent by date of Visit 1a in accordance with good
             clinical practice(GCP) and local legislation

        Exclusion criteria:

          1. Uncontrolled hyperglycaemia required for rescue medication during placebo run-in
             phase

          2. In main group, the patients with investigational medicinal product(IMP) compliance &lt;
             80 % or &gt;120 % during 2 weeks placebo run in period

          3. Acute coronary syndrome stroke or Transient ischaemic attack (TIA) within 3 months
             prior to randomisation

          4. Impaired hepatic function, defined by serum levels of either Alanine
             aminotransferase(ALT) ,Aspartate aminotransferase(AST), or alkaline phosphatase (AP)
             above 3 x upper limit of normal (ULN) ,or total bilirubin above 1.5 x ULN as
             determined at Visit 1a

          5. Known hypersensitivity or allergy to linagliptin or its excipients or metformin or
             placebo

          6. Treatment with anti-obesity drugs 3 months prior to informed consent or any other
             treatment at the time of screening

          7. Alcohol or drug abuse within the 3 months prior to informed consent that would
             interfere with trial participation or any ongoing condition leading to a decreased
             compliance to study procedures or study drug intake in the opinion of the
             investigator.

          8. Concurrent participation in another clinical trial or any investigational therapy
             within thirty days prior to signing the consent form or during the trial.

          9. Pre-menopausal women (last menstruation &lt;/= 1 year prior to informed consent) who are
             nursing or pregnant or are of child-bearing potential and are not practicing an
             acceptable method of birth control, or do not plan to continue using this method
             throughout the study

         10. Current treatment with systemic steroids at time of informed consent or change in
             dosage of thyroid hormones within 6 weeks prior to informed consent.

         11. Renal failure or renal impairment at Visit 1a (screening) with an Estimated
             Glomerular Filtration Rate(eGFR) &lt; 60 ml/min

         12. Bariatric surgery within the past two years and other gastrointestinal surgeries that
             induce chronic malabsorption

         13. Dehydration by clinical judgement of the investigator

         14. Clinical detected unstable or acute congestive heart failure

         15. Acute or chronic metabolic acidosis (present in patient history)

         16. Hereditary galactose intolerance

         17. Known history of pancreatitis and chronic pancreatitis

         18. Medical history of cancer (except for basal cell carcinoma) and/or treatment for
             cancer within last 5 years.

         19. Any other clinical condition that would jeopardize patients safety while
             participating in this clinical trial at the discretion of investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1288.18.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hengshui</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nan Ning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shantou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.86030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yueyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.60004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.60002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melaka</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.60007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Negeri Sembilan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.60005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Negeri Sembilan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.60006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perak</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.60001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perak</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.60008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Putrajaya</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.60003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.63007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.63008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.63006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Surigao</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.63005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tagum City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.84003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.84002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1288.18.84001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>BI 1356</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
